Strata Critical Medical, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 16, 2023 and accepted by EDGAR at Mar 15, 2023, 22:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $146.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $123.8m | us-gaap:CostOfRevenue |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$53.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$772.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$27.3m | us-gaap:NetIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$27.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 71,238,103 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$37.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $730.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $43.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $218.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $325.0m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $26.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $50.5m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-12-31 | $274.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001779128-23-000029. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.